Form 4: Inogen Executive Stanislav Glezer Reports Stock Transactions

Stanislav Glezer, EVP, R&D & Chief Medical Officer of Inogen Inc, reports the vesting and subsequent tax withholding of shares on May 1, 2024.

Summary

• On May 1, 2024, Stanislav Glezer, EVP, R&D & Chief Medical Officer of Inogen Inc., had 32,638 restricted stock units vest.
• These units converted into common stock.
• A portion of the shares (16,695) were withheld to cover the reporting person's tax withholding liability.
• The price per share for the tax withholding was $7.05.
• Following these transactions, Glezer directly owns 32,049 shares of Inogen common stock.

Sentiment

Score: 5

Explanation: This is a routine filing related to executive compensation. It doesn't indicate any significant positive or negative sentiment about the company's performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. This allows investors to track the buying and selling activity of executives and directors, which can provide insights into their perspectives on the company's performance and future prospects.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units that vest over time, aligning executive interests with long-term shareholder value.
• Tax withholding upon vesting of RSUs is a common practice to cover income tax obligations.
• The specific number of shares withheld depends on the executive's tax bracket and the fair market value of the stock at the time of vesting.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it involves the issuance of shares related to existing compensation plans.
• Employees may be interested in the details of executive compensation as it relates to overall company performance.

Key Dates